OVID News and Press, Ovid Therapeutics Inc.

Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...

Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...

The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...

2024-06-30 09:10:33 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead

2024-06-28 15:00:00 ET More on the markets S&P 500: Stay Invested, But Pay Attention To These Risks SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation S&P 500 H1 performance: Market cap vs. Equal weight Biden-Trump pre...

2024-06-18 12:27:47 ET More on Ovid Therapeutics Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 Ovid stock plunges 66% on failed studies for soticlestat Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant...

2024-06-18 10:30:03 ET B. Riley analyst issues BUY recommendation for OVID on June 18, 2024 09:12AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7744 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2024-06-18 07:15:06 ET BTIG analyst issues BUY recommendation for OVID on June 18, 2024 04:51AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7896 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst r...

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 476.9% to $0.75 on volume of 1,104,730,765 shares NVIDIA Corporation (NVDA) fell 0.7% to $130.98 on volume of 283,604,651 shares ENDRA Life Sciences Inc. (NDRA) rose 34.2% to $0.139 on volume of 219,783,92...

A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...